scholarly journals Study of High sensitive C - reactive protein and Gamma-glutamyl transferase in Type 2 Diabetes Mellitus with Hypertension

2020 ◽  
Vol 11 (3) ◽  
pp. 3478-3483
Author(s):  
Ramya S ◽  
Sureka Varalakshmi V ◽  
Uma Maheswari K ◽  
Chandan Bala R
Keyword(s):  
Diabetes Mellitus ◽  
Gamma Glutamyl Transferase ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Significant Difference ◽  
Group A ◽  
Hs Crp ◽  
Group B ◽  
Glutamyl Transferase

C-reactive protein (CRP), produced by the hepatocytes is a primary inflammatory marker of T2DM. Higher levels of gamma-glutamyl transferase enzyme (GGT) and Hs CRP (High sensitive CRP)are associated with the complication of poor glycemic control.This study was aimed to find the association of Hs CRP and GGT for cardiovascular risk factors in Type 2 diabetes mellitus (T2DM)and Hypertension in the suburbs of Chennai. This study includes 57 subjects with T2DM and Hypertension (Group A) and 62 subjects with T2DM (GroupB) within the age group of 40-60 years. FBS, HbA1C, Hs CRP, GGT and blood pressure were determined. Statistical analysis was performed using Statistical Package for the SPSS 17 version. Mean values of FBS, blood HbA1C, Hs CRP and GGT were significantly higher among participants of Group A than Group B. Significant difference of FBS, HbA1C were found between the two groups. In contrast, no significant difference of GGT was found between the groups. Differences were considered statistically significant at two-sided P < 0.05. Within the group, Hs CRP shows the significance and positive correlation with FBS, SBP and DBP. Still, GGT does not show any significance in Group A. In contrast, in Group B, both Hs CRP and GGT shows the importance and positive correlation with FBS and HbA1C.It is concluded that high levels of HsCRP are associated with T2DM and Hypertension, indicating increased cardiovascular risk, and it should be included in regular monitoring of type-2 diabetic patients.

scholarly journals C-Reactive Protein Predicts Progression of Peripheral Arterial Disease in Patients with Type 2 Diabetes: A 5-Year Follow-Up Study

2014 ◽  
Vol 33 (4) ◽  
pp. 347-355
Author(s):  
Ljiljana Popović ◽  
Katarina Lalić ◽  
Olga Vasović ◽  
Danijela Drašković Radojković ◽  
Nataša Rajković ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Peripheral Arterial Disease ◽  
Arterial Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Group A ◽  
Hs Crp ◽  
Group B ◽  
Peripheral Arterial

Summary Background: Previous studies have indicated that high sensitivity C-reactive protein (hs-CRP) is a risk factor for the peripheral arterial disease (PAD) in diabetes. This study aimed to evaluate the possible predictive significance of hs-CRP for the development and progression of PAD in patients with type 2 diabetes (T2D). Methods: The study included 80 patients previously diagnosed with T2D, aged 45–70 years, divided into group A (T2D patients with PAD; n=38) and group B (T2D patients without PAD; n=42). After five years, all the patients were re-examined and divided into subgroups depending on de novo development of PAD or progression of previously diagnosed PAD. Ankle-Brachial Index (ABI) measurement was used for PAD diagnosis and hs-CRP was determined by nephelometry. Results: We found significantly higher hs-CRP levels in group A compared to group B, but only at baseline. Among the patients in group A, those with later progression of PAD (subgroup A1) had the highest levels of hs-CRP at baseline, although not significantly different from those in subgroup A2 (non-progressors). In contrast, hs-CRP level was significantly higher in subgroup B1 (progressors) in comparison to subgroup B2 (non-progressors) at both the first and second exam. Of all the investigated metabolic parameters, hs-CRP was the only independent predictor of PAD progression (OR=0.456, 95% CI=0.267–0.7815, p=0.004). The cut-off point for hs-CRP was 2.5 mg/L (specificity 75% and sensitivity 73.3%) with the relative risk for PAD of 2.93 (95% CI=1.351–6.3629). Conclusions: Our study implies that hs-CRP can be used as a reliable predictor for the progression of PAD in patients with T2D.

C-reactive protein as a marker of progression of carotid atherosclerosis in subjects with type 2 diabetes mellitus

VASA ◽  
2017 ◽  
Vol 46 (3) ◽  
pp. 187-192 ◽  
Author(s):  
Aleš Pleskovič ◽  
Marija Šantl Letonja ◽  
Andreja Cokan Vujkovac ◽  
Jovana Nikolajević Starčević ◽  
Katarina Gazdikova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Carotid Atherosclerosis ◽  
Inflammatory Marker ◽  
Progression Rate ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp ◽  
Unstable Plaques

Abstract. Background: This prospective study was designed to evaluate the effect of inflammatory markers on the presence and progression of subclinical markers of carotid atherosclerosis in a 3.8-year follow-up period in patients with type 2 diabetes mellitus (T2DM). Patients and methods: A total of 595 subjects with T2DM were enrolled. Subclinical markers of carotid atherosclerosis (carotid intima media thickness (CIMT), plaque thickness, and plaques presence) were assessed with ultrasound at the time of recruitment and again after 3.8 years. Subjects with T2DM were divided into 2 groups according to the plasma high sensitive C-reactive protein (hs-CRP) levels (subjects with hs-CRP ≥ 2 mg/L and subjects with hs-CRP below 2 mg/L). Results: Subjects with T2DM and hs-CRP levels ≥ 2 mg/L had higher CIMT in comparison with subjects with T2DM and hs-CRP levels below 2 mg/L, and higher incidence of plaques/unstable plaques in comparison with subjects with T2DM and hs-CRP levels below 2 mg/L. Multivariate logistic regression analysis found the association between the HDL cholesterol level and presence of plaques, whereas the inflammatory marker hs-CRP was not associated with subclinical markers of progression of carotid atherosclerosis. Multiple linear regression analysis found the association between the hs-CRP levels and either CIMT progression rate or a change in the number of sites with plaques in a 3.8-year follow-up. Conclusions: We demonstrated an association between the inflammatory marker hs-CRP and either CIMT or incidence of plaques/unstable plaques at the time of recruitment in Caucasians with T2DM. Moreover, we found the association between hs-CRP levels and either CIMT progression rate or a change in the number of sites with plaques in a 3.8-year follow-up in subjects with T2DM.

Investigation of the inflammatory biomarkers of metabolic syndrome in adolescents

2016 ◽  
Vol 0 (0) ◽  
Author(s):  
Ummugulsum Can ◽  
Muammer Buyukinan ◽  
Asuman Guzelant ◽  
Ayse Ugur ◽  
Adnan Karaibrahimoglu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Serum Levels ◽  
Inflammatory Biomarkers ◽  
Low Grade ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Hs Crp ◽  
Age And Sex

AbstractBackground:Metabolic syndrome (MetS) is a chronic and multifactorial syndrome characterized by a low-grade chronic inflammation, and a major risk factor for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). In our study, we aimed to investigate the serum levels of high sensitive C-reactive protein (hs-CRP), haptoglobin (Hp), αMethods:This study was performed in 43 (18 males, 25 females) MetS adolescents between the ages of 13 and 17 years (14.70±1.15) and 43 lean controls were matched for age and sex. The serum levels of Hp, αResults:Serum Hp, fetuin-A (p<0.01) and PF-4, hs-CRP, SAP, AGP (p<0.001) values of the MetS subjects were significantly higher than those of the controls. No difference was found in serum αConclusions:This finding suggests the possibility of using these markers in diagnosis of MetS in adolescents to prevent future complications.

scholarly journals High-sensitivity C-reactive protein in subjects with type 2 diabetes mellitus and/or high blood pressure

2007 ◽  
Vol 51 (6) ◽  
pp. 956-960 ◽  
Author(s):  
Luciana M. Lima ◽  
Maria das Graças Carvalho ◽  
Anna L. Soares ◽  
Adriano de P. Sabino ◽  
Ana P. Fernandes ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
High Sensitivity ◽  
Normal Subjects ◽  
C Reactive Protein ◽  
Hypertensive Patients ◽  
Reactive Protein ◽  
Hs Crp

Type 2 diabetes mellitus (DM2) and high blood pressure (HBP) may contribute to the development of cardiovascular disease, and inflammation may be an important factor in these diseases. In the present study, plasma levels of high-sensitivity C-reactive protein (hs-CRP) were measured in subjects with DM2 and/or HBP and compared to those of normal subjects. Eighty-nine subjects were analyzed for hs-CRP, including 13 normotensive patients with DM2, 17 patients with HBP, 34 hypertensive patients with DM2 (DM2+HBP) and 25 normal subjects. The plasma hs-CRP levels were significantly lower in the controls than in the HBP+DM2 group (p < 0.05). DM2 associated with HBP was also correlated with increased plasma hs-CRP levels (n = 89, r = 0.25, p = 0.0162). Only hypertensive patients with DM2 had higher levels of hs-CRP, a circulating inflammatory marker, than normal subjects. This finding suggests that patients with two associated diseases have a more active inflammatory state.

scholarly journals A study of high sensitive C-reactive protein in rheumatoid arthritis patients

2020 ◽  
Vol 9 (1) ◽  
pp. 139
Author(s):  
Priyanka Meena ◽  
Sourabh Goswami ◽  
Ajay Mathur ◽  
Ramji Sharma
Keyword(s):  
Rheumatoid Arthritis ◽  
C Reactive Protein ◽  
Dmard Therapy ◽  
Random Blood Sugar ◽  
Reactive Protein ◽  
Early Ra ◽  
Group A ◽  
The Mean ◽  
Hs Crp ◽  
Group B

Background: Rheumatoid arthritis (RA) is not only merely limited to joints but has many extraarticular features. The major cause of mortality in RA is cardiovascular disease (CVD). Inflammation in RA predispose them to succumb to CVD. The aim of this study to observe whether therapy with disease-modifying anti-rheumatic drugs (DMARD) decreases inflammation and if it does so than it can be said that decrease the risk to develop CVD. Aim and objectives were to assess hs-CRP level in early and established RA both at diagnosis and again at 3 months of DMARD therapy and compare between them.Methods: Total 58 early RA (group A) and 58 established (group B) DMARD naïve RA patients were included in the study. Age, BMI, haemoglobin, random blood sugar, lipid profile, ESR, hs-CRP, RA factor and anti-CCP were measured. All of them were treated with DMARD and hs-CRP was again assessed after 3 months.Results: The mean hs-CRP level at diagnosis was 6.14±1.90 mg/l in group A while it was 10.39±3.13 mg/l in group B. The mean hs-CRP level after 3 months of DMARD was 2.56±1.35mg/l in group A while it was 7.91±3.13 mg/l in group B. The mean reduction in hs-CRP level in early RA (3.58±0.99 mg/l) was statistically significantly (p<0.001) higher than that in established RA (2.48±0.09 mg/l).  Conclusions: DMARD decreases level of inflammation in RA more efficiently if initiated early in the course of the disease.

scholarly journals To compare rosuvastatin with atorvastatin in terms of mean change in LDL-C in patient of diabetes mellitus.

2020 ◽  
Vol 27 (07) ◽  
pp. 1505-1510
Author(s):  
Masood Javed ◽  
Dilshad Mohammad ◽  
Muzzammal Iftikhar ◽  
Mohsin Jameel ◽  
Zain Masood ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Close Association ◽  
P Value ◽  
Significant Difference ◽  
Group A ◽  
Control Of Diabetes ◽  
Insignificant Difference ◽  
Group B ◽  
And Control

Diabetes Mellitus is a very common metabolic disorder characterized by hyperglycemia and altered metabolism of lipids, proteins and carbohydrates due to absolute or relative insulin deficiency or insulin resistance. There is a close association between complications of Diabetes and Diabetic Dyslipidemias. The lowering of LDL levels with statins varies from 20 to 60% and greatest effects are seen with the most potent statins such as Atorvastatin, and Rosuvastatin in higher doses. Objectives: The objective of the study was; to compare Rosuvastatin with Atorvastatin in terms of mean change in LDL-C in patients of Diabetes Mellitus. Study Design: Randomized Control Trail. Setting: Department of Medicine DHQ Hospital, Faisalabad. Period: Six months from 01/10/2018 to 31/03/2019. Material & Methods: Results: A total of 160 cases (80 in each group) fulfilling the inclusive/exclusive criteria were enrolled to compare Rosuvastatin with Atorvastatin in terms of mean change in LDL-C in patients of Diabetes Mellitus. Mean LDL-C levels at baseline was recorded as159.61+1.22 in Group-A and 159.51+1.21 in Group-B, p value was calculated as 0.603 showing insignificant difference. Mean LDL-C after 6 weeks of treatment was recorded as129.11p+1.50 in Group-A and 129.89+2.23 in Group-B, p value was calculated as 0.01 showing significant difference. Mean change in LDL-C level after 6 weeks of treatment was recorded as 30.5+1.88 in Group-A and 29.63+2.57 in Group-B, p value was calculated as 0.01 showing a significant difference. The data was stratified for Age, Gender, Duration of Diabetes Mellitus and control of Diabetes Mellitus. Conclusion:  This study proves superiority of Rosuvastain over Atorvastatin in reducing LDL-C level in type 2 DM Patients.

Positive Association Between Serum Levels of High-Sensitivity C-Reactive Protein and Depression/Anxiety in Female, but Not Male, Patients With Type 2 Diabetes Mellitus

2019 ◽  
Vol 22 (2) ◽  
pp. 178-187 ◽  
Author(s):  
Qian-Qian Yang ◽  
Di Shao ◽  
Jie Li ◽  
Chun-Ling Yang ◽  
Min-Hua Fan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Positive Association ◽  
High Sensitivity ◽  
Depression And Anxiety ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Symptoms Of Depression ◽  
Hs Crp

Purpose: Patients with Type 2 diabetes (T2D) have increased risk of depression and anxiety. Evidence suggests that a heightened inflammatory state may contribute to this association. Females experience more depression and higher inflammation levels than males. This study compared associations of serum high-sensitivity C-reactive protein (hs-CRP) levels with symptoms of depression and anxiety between men and women with Type 2 diabetes mellitus (T2DM). Method: Cross-sectional data including demographic and disease characteristics, symptoms of depression and anxiety, clinical data, and laboratory values were collected from 392 patients with T2DM recruited from a general hospital in Shandong Province, China. We evaluated associations between serum hs-CRP level and symptoms of depression and anxiety in males and females separately using multiple linear regressions and χ2 tests for trend. Results: Sex moderated the association between serum hs-CRP level and symptoms of depression ( B = .112 [ SE = 0.049]; p = .022) and anxiety ( B = .137 [ SE = 0.053]; p = .011). Among females, hs-CRP level was positively associated with depression ( B = .034, 95% confidence interval [CI] = [.006, .061]; p = .016, false discovery rate [FDR]-adjusted p = .020) and anxiety ( B = .041, 95% CI [.011, .071], p = .007, FDR-adjusted p = .007). Positive trends indicated a higher prevalence of clinically significant symptoms of depression and anxiety in higher serum hs-CRP categories in females. No associations were found in males. Conclusion: Findings demonstrate that associations between serum hs-CRP level and symptoms of depression and anxiety in patients with T2D are sex-specific, with only females demonstrating a significant positive association.

scholarly journals Effect of Metformin on C-reactive Protein in Type 2 Diabetes Mellitus Patients

2021 ◽  
pp. 53-61
Author(s):  
P Selvi ◽  
Arul Amutha Elizabeth
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Vascular Complications ◽  
Diabetic Patients ◽  
C Reactive Protein ◽  
Metformin Therapy ◽  
Reactive Protein ◽  
Increased Risk ◽  
Hs Crp

Diabetes mellitus (DM) is a complex endocrinology disease which requires a meticulous understanding of its pathogenesis and its complications to subdue it. It has been riddled with extensive micro and macro vascular complications which by itself has its own set of pathogenesis. There is a link between DM and cardiovascular disease (CVD), which is the most important cause of morbidity and mortality in diabetic patients. Cardiovascular risk factors such as obesity, hypertension and dyslipidemia are more common in patients with DM, placing them at increased risk for cardiac events.  In addition, they have found biological mechanisms associated with DM that independently increases the risk of CVD in diabetic patients.Metformin is the most commonly used antidiabetic agent derived from Gallegaofficinalis. Metformin provided greater protection against macro vascular complications than would be expected from its effects upon glycemic control alone. Hence this study evaluated the anti-inflammatory effect of metformin on C Reactive Protein (CRP) in patients. In this study fifty type 2 diabetes patients were enrolled in the study including 23 males and 27 females with mean age 40±4.33. FBS and PPBS baseline values expressed as Mean ± SD were 138.06±17.12 mg/dl and 223.12±30.63 mg/dl respectively. After 6 months of metformin therapy, FBS and PPBS were 91.64±10.55 mg/dl and 133.88±7.99 mg/dl respectively. HBA1C baseline value expressed as Mean ± SD was 7.966±0.85 %. After 6 months of metformin therapy, HBA1C improved to 6.8±0.93.hs-CRP baseline value expressed as Mean±SD was 3.4±1.16 mg/L. After 6 months of metformin therapy, hs - CRP effectively reduced to 1.7±0.81 mg/L. Prompt treatment intensification in such cases may thus be sensible. Further studies are needed to identify predictors of metformin treatment response, especially focusing on hs-CRP levels, lipid levels and genetic factors.

Sign in / Sign up

Export Citation Format

Share Document